Clinical Trials Browser

Phase 2 × Not yet recruiting × Febrile Neutropenia × Clear all

NCT06143735 2023-11-22

A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors

Phase 2 Not yet recruiting

Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Febrile Neutropenia